CDKN2A and endometrial carcinoma: The Anti-p16 INK4a antibody [clone BC42] has been already tested on various normal (30 types) and neoplastic tissues (12 types), revealing equivalent exceptional staining quality, high levels of sensitivity and specificity compared to the current used clone E6H4, in particular in: Cervical adenocarcinoma (22 cases); cervical intraepithelial neoplasia (CIN) (24 cases); cervical squamous carcinoma (16 cases); head and neck cancer (12 cases); endometrial carcinoma (48 cases) and ovarian cancer (12 cases) [51].